UNSPSC 51432503: Perindopril

This classification denotes an ace inhibitor with the molecular formula C19H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y5GMK36KGY, chemically known as 11h-indole-2-carboxylic acid, octahydro-1-(2-((1-ethoxycarbonyl)butyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-beta,7a-beta))- but generally known as perindopril, which bears US NIH Compound Identifier 60184. European Medicines Agency schedules Perindopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09730MIG.

UNSPSC 51432503 Perindopril is a Commodity code representing individual pharmaceutical products purchased by state and local government health and public safety agencies. Recent solicitations under this code show state and local buyers procuring specific branded and generic medications for emergency medical services, health benefit programs, and institutional pharmacy networks. The City of Tampa's April 2026 IFB for Advanced Life Support Medications illustrates typical scope: sealed-bid procurement of injectable medications in defined quantities (370 units of Labetalol, 1,810 units of Epinephrine, 330 units of Adenosine, 1,020 units of Diltiazem) for use by Tampa Fire Rescue, with firm pricing, FOB delivery within ten calendar days, and nine-month minimum expiration requirements. Issuing bodies soliciting under this code include municipal fire and emergency services departments, state health agencies managing pharmacy benefit programs, and cooperative purchasing alliances representing multiple jurisdictions. The Texas Health and Human Services Commission's April 2026 RFI on direct-to-manufacturer pharmacy initiatives and the Minnesota Multistate Cooperative Purchasing Alliance's January 2026 RFP for generic multi-source pharmaceuticals distributed through authorized wholesalers signal state-level interest in alternative contracting models that bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity concentrates in Texas, Florida, and Minnesota, with cooperative purchasing mechanisms extending reach across multiple states including Oregon. Tampa's IFB carries an estimated contract value of $40,000 with a one-year term and two optional renewals, featuring a 5 percent SLBE bid discount capped at $10,000. The Minnesota MMCAP RFP requires submission by March 26, 2026, establishes a two-year initial term, mandates 3 percent administrative fees on all purchases, and imposes performance penalties of $200 to $1,500 per violation for late reporting or onboarding failures; awarded vendors must contract with at least two of three specified wholesalers (Cencora, Cardinal Health, Morris & Dickson) and comply with cGMP and DSCSA certification. Vendors pursuing this code face competitive pressure on unit pricing (75 percent of MMCAP evaluation weight), mandatory compliance with FDA expiration and shelf-life standards, and increasing state preference for direct manufacturer relationships that reduce intermediary markups in pharmacy benefit administration.